QIAGEN Completes Acquisition of eGene
eGene, located in Irvine, California, has developed a multi-channel sample separation and analysis technology for nucleic acids based on capillary electrophoresis that includes an affordable and robust instrument, software analysis package, and a selection of consumable cartridges especially designed for specific high-value applications in the molecular diagnostic and research markets. The HDA-GT12™ Genetic Analyzer incorporates many capabilities into one easy to use platform, integrating automatic sample loading, separation, and data analysis. Next generation products will most likely include an expanded menu of products targeting use in research, applied testing and molecular diagnostics and may be combined with QIAGEN’s QIAplex technology.
As QIAGEN announced on April 12, 2007, QIAGEN expects this transaction to contribute approximately $2 million in sales in the second half of 2007 and roughly $7-$9 million in sales for the full year in 2008. QIAGEN expects to incur one-time charges of approximately $0.01 in EPS in the third quarter 2007. These charges primarily relate to in-process research and development and the write-off of certain assets. On an adjusted basis excluding one-time charges, integration and restructuring costs and amortization of acquired IP, the acquisition is expected to reduce EPS in the second half of 2007 by approximately $0.01 and to be neutral to earnings in 2008. Beyond 2008, revenues for this product line are expected to grow rapidly and contribute significant accretion to net income as the instrument base expands and drives increasing consumable usage.
QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,800 people in more than 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.